Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
about
Characterization of PET/CT images using texture analysis: the past, the present… any future?Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-IIIEarly Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET.Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis.Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot StudyTLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology.Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy.Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib.Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up.Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma.Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.The effects of segmentation algorithms on the measurement of 18F-FDG PET texture parameters in non-small cell lung cancerDevelopments in oncological positron emission tomography/computed tomography assessment.Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy.The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.Predicting survival time of lung cancer patients using radiomic analysis.Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma.Clinical applications of textural analysis in non-small cell lung cancer.Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.Assessment of intratumor heterogeneity in mesenchymal uterine tumor by an 18F-FDG PET/CT texture analysis.PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet?Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma.Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy.Assessment of very early response evaluation with 18F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methods.The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer
P2860
Q30837034-1AD1901E-FB0F-4709-8C71-2CBDA53AE7D9Q33617538-45A825B1-0509-4EB3-90B4-B1172B92A1A1Q36056706-933D9D4B-4D89-4082-BF5C-8796EEADEB5EQ37136741-A7A95E9E-C635-4CF9-8648-493D68F24574Q37566580-188AB9BE-C6A9-4720-89A1-5B1244E1020AQ37701724-4ABA519D-9595-4FB0-86E4-310D1769D82BQ38739306-596E0D39-E5A0-4B4A-A42C-696881BB0C2EQ38798562-A3807751-380E-4350-8935-718631A42592Q38841400-B485C26C-F31B-431A-BF63-415C2730BE0FQ38853578-E90AB716-201A-4091-A7D1-DF502580518FQ39197536-BFC3A973-49FA-415C-9170-AEAFD2B04E0CQ39405075-D3FF9D62-107C-4428-8E0D-229C94A77D35Q39433202-3B10A128-EFDF-479C-8CBF-F57EC4A6CF0AQ39933893-051C53B2-47DE-4A85-B91E-15AECA5B709DQ40000698-D8F4380F-1225-4A75-848C-0A1B59DB9549Q40643000-9A439F97-C518-4314-B668-52791D432574Q41139552-C1A21E84-D9C1-4F42-B384-AD141A52FE02Q41965876-1D8AC749-17A6-4A0F-812D-24F9C5A4BCBFQ42365356-5719A568-9F99-4197-B916-80263A492929Q45215365-9CBCA6FE-0367-4329-85B2-3C76AC6A6111Q47120003-825B5683-AEDF-49D8-8606-8A858E1205B0Q47850078-90089234-C46F-45B9-950E-02AC86BA2CF4Q47966288-859CB8CF-98CD-45CF-927A-BB9F3FD0E61FQ48047542-C52B099F-B2E4-4ECC-B960-D2880BCDAEB1Q50110161-C6A6873A-ED93-46ED-8062-4FE93021386CQ50326521-234136B0-661F-4997-8EB4-7D8A31B8A6EAQ50894106-F9ED644A-5ED7-4B1E-930D-A3B6CAE03F09Q51736041-CA3906DE-550B-41A1-A7AF-00E512303F3FQ54965644-2E67B97E-7B06-4B8F-95F0-3F678827C2ACQ57172944-61CAC5F2-BD5E-4C2E-B9EE-D3E4B8DC90C1
P2860
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Non-Small Cell Lung Cancer Tre ...... atment Response and Prognosis.
@en
type
label
Non-Small Cell Lung Cancer Tre ...... atment Response and Prognosis.
@en
prefLabel
Non-Small Cell Lung Cancer Tre ...... atment Response and Prognosis.
@en
P2093
P50
P1433
P1476
Non-Small Cell Lung Cancer Tre ...... eatment Response and Prognosis
@en
P2093
Bhupinder Sharma
Mary E O'Brien
Muhammad Siddique
Ravi Punwani
Sugama Chicklore
P304
P356
10.1148/RADIOL.2015141309
P407
P577
2015-04-17T00:00:00Z